Health News

FDA: Don't Take Diamond 3500
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Diamond 3500, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
FDA Warns Against Sex Enhancement Pill
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Eros Power Zone 1900, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
ED Supplement May Pose Health Risk
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Triple MiracleZen Gold 1750 mg, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
Male Enhancement Product May Pose Health Risk
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Xtra Zone 2400, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
How Heart Attacks Affect Life Expectancy
After a heart attack, life expectancy can depend on many factors. Now new evidence suggests that even a patient's sex and skin color may play a role.
Are You at Risk for Heart Disease?
Heart disease remains the leading cause of death in the US, but watching for certain risk factors may help give your heart a chance.
Screening for Disease: What Are the Benefits?
Screening for cancer and other serious diseases is the norm, but does it always help patients?
Retired...From Taking Meds?
Retirement can be a liberating time for many people. But with this huge life transition, people's habits may change. They might even stop taking their medications as prescribed.
Know Your Kidneys and Spread the Word
During National Kidney Month in March, The National Kidney Disease Education Program (NKDEP) seeks to raise awareness about kidney health.
FDA: Blood Pressure Medication Warning
The U.S. Food and Drug Administration (FDA) is warning of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) in patients with diabetes or kidney (renal) impairment.